Lisata Therapeutics Q3 EPS $(0.65) Beats $(0.93) Estimate
Portfolio Pulse from bharat@benzinga.com
Lisata Therapeutics reported Q3 losses of $(0.65) per share, beating the analyst consensus estimate of $(0.93) by 30.11%. This represents a 56.08% increase over losses from the same period last year.
November 02, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics' Q3 losses were less than expected, which could be seen as a positive sign by investors.
Lisata Therapeutics reported lower than expected losses for Q3, which could be interpreted as a positive sign by investors. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100